PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lessened its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCTFree Report) by 21.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 393,540 shares of the company’s stock after selling 109,063 shares during the period. Mirae Asset Global Investments Co. Ltd. owned approximately 0.77% of PROCEPT BioRobotics worth $19,449,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Fairman Group LLC acquired a new position in PROCEPT BioRobotics in the fourth quarter valued at about $84,000. Blue Trust Inc. lifted its holdings in shares of PROCEPT BioRobotics by 30.9% in the 4th quarter. Blue Trust Inc. now owns 2,629 shares of the company’s stock worth $110,000 after acquiring an additional 620 shares during the last quarter. Glass Jacobson Investment Advisors llc acquired a new position in shares of PROCEPT BioRobotics in the 4th quarter worth approximately $138,000. Jump Financial LLC purchased a new position in shares of PROCEPT BioRobotics during the 4th quarter worth approximately $201,000. Finally, Amalgamated Bank increased its holdings in PROCEPT BioRobotics by 5.8% in the 4th quarter. Amalgamated Bank now owns 5,804 shares of the company’s stock valued at $243,000 after purchasing an additional 316 shares during the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Alaleh Nouri sold 10,000 shares of the business’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $62.18, for a total transaction of $621,800.00. Following the completion of the transaction, the executive vice president now owns 52,472 shares in the company, valued at $3,262,708.96. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other PROCEPT BioRobotics news, EVP Hisham Shiblaq sold 26,046 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $68.24, for a total value of $1,777,379.04. Following the transaction, the executive vice president now directly owns 55,860 shares in the company, valued at $3,811,886.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Alaleh Nouri sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $62.18, for a total transaction of $621,800.00. Following the sale, the executive vice president now directly owns 52,472 shares in the company, valued at approximately $3,262,708.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 86,478 shares of company stock worth $5,515,482. 17.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on PRCT shares. Truist Financial raised their price target on PROCEPT BioRobotics from $63.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Piper Sandler increased their price target on shares of PROCEPT BioRobotics from $67.00 to $75.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. Finally, TD Cowen lifted their price objective on shares of PROCEPT BioRobotics from $65.00 to $75.00 and gave the company a “buy” rating in a report on Monday, May 6th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, PROCEPT BioRobotics currently has an average rating of “Buy” and an average target price of $61.20.

View Our Latest Analysis on PROCEPT BioRobotics

PROCEPT BioRobotics Trading Up 1.7 %

Shares of NASDAQ PRCT opened at $64.69 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.44 and a current ratio of 8.52. The stock’s 50-day moving average is $63.71 and its two-hundred day moving average is $53.30. PROCEPT BioRobotics Co. has a 1-year low of $24.83 and a 1-year high of $77.00.

PROCEPT BioRobotics (NASDAQ:PRCTGet Free Report) last released its earnings results on Wednesday, May 1st. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.04. PROCEPT BioRobotics had a negative net margin of 66.12% and a negative return on equity of 41.35%. The firm had revenue of $44.50 million for the quarter, compared to analyst estimates of $41.58 million. During the same period in the prior year, the firm earned ($0.63) earnings per share. The business’s quarterly revenue was up 82.4% compared to the same quarter last year. Analysts anticipate that PROCEPT BioRobotics Co. will post -1.93 EPS for the current fiscal year.

PROCEPT BioRobotics Profile

(Free Report)

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

Further Reading

Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Co. (NASDAQ:PRCTFree Report).

Institutional Ownership by Quarter for PROCEPT BioRobotics (NASDAQ:PRCT)

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.